AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9504725 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative EEG deficit
Number of subjects: 62
Study 9504725 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological performance
Number of subjects: 62
Study 7520770 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF 5 micrograms/kg every 12 hours
Number of subjects: 42
Study 7520770 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF 10 micrograms/kg every 12 hours
Number of subjects: 42
Study 7520770 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF 1.0, 5.0 or 10.0 micrograms/kg every 24 hours
Number of subjects: 42
Study 7520770 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 42
Study 7520770 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF 10 micrograms/kg every 24 hours
Number of subjects: 42
Study 7520770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2472722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive (Beriplast) applied to the gallbladder bed
Number of subjects: 80
Study 2472722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin adhesive)
Number of subjects: 80
Study 30095858 — intervention group
Group type: EXPERIMENTAL
Intervention: burst-TENS-CT
Number of subjects: 70
Study 30095858 — intervention group
Group type: EXPERIMENTAL
Intervention: AMF-CT
Number of subjects: 70
Study 30095858 — intervention group
Group type: COMPARATOR
Intervention: sham-CT
Number of subjects: 70
Study 28159819 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model using preprocedural clinical variables (13 variables selected from 83)
Number of subjects: 8800
Study 28159819 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning method of random forest
Number of subjects: 8800
Study 26244434 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 26244434 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol
Number of subjects: 0
Study 26244434 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 23574713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid vaginal gel (Hyalofemme)
Number of subjects: 144
Study 23574713 — intervention group
Group type: COMPARATOR
Intervention: Estriol cream (Ovestin)
Number of subjects: 144
Study 22509426 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor bone marrow infusion (DBMI)
Number of subjects: 40
Study 22509426 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 40
Study 18222275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32 degrees C)
Number of subjects: 30
Study 18222275 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia (25 degrees C)
Number of subjects: 30
Study 18222275 — intervention group
Group type: EXPERIMENTAL
Intervention: Long CPB time and long aortic cross‐clamp time
Number of subjects: 30
Study 15967546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (15 mg/16 hr)
Number of subjects: 40
Study 12907325 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg once daily
Number of subjects: 680
Study 12907325 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 680
Study 12907325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 12907325 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 680
Study 12907325 — intervention group
Group type: COMPARATOR
Intervention: Nonselective NSAIDs (ibuprofen, naproxen, or diclofenac)
Number of subjects: 680
Study 10234793 — intervention group
Group type: EXPERIMENTAL
Intervention: P-ESWL (Pulverization, no chemolitholysis)
Number of subjects: 34
Study 10234793 — intervention group
Group type: COMPARATOR
Intervention: F-ESWL (fragments <= 4 mm, concomitant oral chemolitholysis)
Number of subjects: 34
Study 10234793 — intervention group
Group type: EXPERIMENTAL
Intervention: P-ESWL
Number of subjects: 34
Study 8909622 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE program (all three components: Rites of Passage, summer employment, entrepreneurial experience)
Number of subjects: 260
Study 8909622 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer employment and entrepreneurial components only
Number of subjects: 260
Study 8909622 — intervention group
Group type: COMPARATOR
Intervention: Delayed program or control condition
Number of subjects: 260
Study 2062518 — intervention group
Group type: COMPARATOR
Intervention: 50% nitrous oxide/50% oxygen and placebo
Number of subjects: 40
Study 2062518 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen and 20 mg diazepam
Number of subjects: 40
Study 2062518 — intervention group
Group type: COMPARATOR
Intervention: 50% nitrous oxide/50% oxygen and 20 mg diazepam
Number of subjects: 40
Study 6613711 — intervention group
Group type: EXPERIMENTAL
Intervention: Male smoking confederate
Number of subjects: 56
Study 6613711 — intervention group
Group type: EXPERIMENTAL
Intervention: Female smoking confederate
Number of subjects: 56
Study 6613711 — intervention group
Group type: COMPARATOR
Intervention: No model present
Number of subjects: 56
Study 30700328 — intervention group
Group type: EXPERIMENTAL
Intervention: pTVG-HP DNA vaccine and pembrolizumab
Number of subjects: 17
Study 30700328 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FLT uptake in the thyroid
Number of subjects: 17
Study 29336187 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab 50 mg every 4 weeks (q4w)
Number of subjects: 168
Study 29336187 — intervention group
Group type: EXPERIMENTAL
Intervention: sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 168
Study 29336187 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 168
Study 26580978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suspension eye-drops (group A)
Number of subjects: 117
Study 26580978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone solution eye-drops (group B)
Number of subjects: 117
Study 26580978 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 117
Study 24701009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BFECT)
Number of subjects: 70
Study 24701009 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal ECT (BTECT)
Number of subjects: 70
Study 22379064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 2
Study 22379064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 20215457 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII/RT‐CGM with the algorithm
Number of subjects: 60
Study 20215457 — intervention group
Group type: COMPARATOR
Intervention: CSII/RT‐CGM without the algorithm
Number of subjects: 60
Study 17488683 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood (PB) monitoring for minimal residual disease (MRD)
Number of subjects: 50
Study 18694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self administered questionnaire on computer
Number of subjects: 0
Study 18694046 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper based method
Number of subjects: 0
Study 12569085 — intervention group
Group type: EXPERIMENTAL
Intervention: C + AA (hydrocortisone sodium succinate infusion at 80 microg. kg(‐1). h(‐1))
Number of subjects: 12
Study 12569085 — intervention group
Group type: COMPARATOR
Intervention: AA (intravenous saline)
Number of subjects: 12
Study 11126816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (2 mg intravenously at induction)
Number of subjects: 50
Study 11126816 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 50
Study 11126816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11126816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 50
Study 9175044 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo therapy (50 IU/kg intravenously or 35 IU/kg subcutaneously for the first 6 months, then 20 IU/kg)
Number of subjects: 33
Study 9175044 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo therapy
Number of subjects: 33
Study 1543940 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrated calcium carbimide with relapse prevention counselling
Number of subjects: 56
Study 1543940 — intervention group
Group type: COMPARATOR
Intervention: Citrated calcium carbimide with Physician Advice
Number of subjects: 56
Study 3907677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyfedrine 24 mg four times daily
Number of subjects: 0
Study 3907677 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 0
Study 30465815 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min high-intensity cycling exercise
Number of subjects: 29
Study 30465815 — intervention group
Group type: COMPARATOR
Intervention: Resting control session
Number of subjects: 29
Study 29193677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallic Acid (GA) 15 mg p-1 d-1 for 7 days
Number of subjects: 19
Study 26891345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-related alcohol expectancies (increased riskiness, decreased nervousness, enhanced sexuality)
Number of subjects: 126
Study 26891345 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting
Number of subjects: 126
Study 24717407 — intervention group
Group type: EXPERIMENTAL
Intervention: TIROX regimen (S‐1 + irinotecan + oxaliplatin)
Number of subjects: 60
Study 24717407 — intervention group
Group type: COMPARATOR
Intervention: DCF regimen (docetaxel + cisplatin + flurouracil)
Number of subjects: 60
Study 24717407 — intervention group
Group type: EXPERIMENTAL
Intervention: TIROX regimen
Number of subjects: 60
Study 24717407 — intervention group
Group type: COMPARATOR
Intervention: DCF regimen
Number of subjects: 60
Study 22200343 — intervention group
Group type: COMPARATOR
Intervention: EBPI brochure (n = 66)
Number of subjects: 132
Study 22200343 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA brochure (n = 66)
Number of subjects: 132
Study 22200343 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with attitude change
Number of subjects: 132
Study 22200343 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with intention change
Number of subjects: 132
Study 19935115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage therapy (BT)
Number of subjects: 92
Study 19935115 — intervention group
Group type: COMPARATOR
Intervention: Cast therapy (CT)
Number of subjects: 92
Study 19935115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage therapy (BT) and Cast therapy (CT)
Number of subjects: 92
Study 18565440 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER social marketing campaign
Number of subjects: 3407
Study 18565440 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER exposure
Number of subjects: 3407
Study 18565440 — intervention group
Group type: COMPARATOR
Intervention: Control (no POWER campaign)
Number of subjects: 3407
Study 16214916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of elemental calcium daily for 4 years
Number of subjects: 2051
Study 16214916 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin daily for 3 years combined with calcium supplementation
Number of subjects: 2051
Study 16214916 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dietary calcium intake
Number of subjects: 2051
Study 12205831 — intervention group
Group type: EXPERIMENTAL
Intervention: CAHPS report
Number of subjects: 0
Study 12205831 — intervention group
Group type: COMPARATOR
Intervention: Standard Medicaid enrollment materials
Number of subjects: 0
Study 10323511 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma N-terminal atrial natriuretic peptide prohormone measurement
Number of subjects: 68
Study 10323511 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis of hemodynamic and clinical variables
Number of subjects: 68
Study 7478874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice plus imagery practice
Number of subjects: 32
Study 7478874 — intervention group
Group type: COMPARATOR
Intervention: Physical practice only
Number of subjects: 32
Study 1932261 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental and classical conditioning combined
Number of subjects: 50
Study 1932261 — intervention group
Group type: COMPARATOR
Intervention: Instrumental conditioning alone
Number of subjects: 50
Study 1932261 — intervention group
Group type: COMPARATOR
Intervention: Classical conditioning alone
Number of subjects: 50
Study 1932261 — intervention group
Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 50
Study 1932261 — intervention group
Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 50
Study 6344035 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 5
Study 6344035 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 5
Study 6344035 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + Propranolol 80 mg
Number of subjects: 5
Study 6344035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31623572 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular QLB (QLB‐3) using 20 ml 0.25% bupivacaine
Number of subjects: 40
Study 31623572 — intervention group
Group type: COMPARATOR
Intervention: Posterior QLB (QLB‐2) using 20 ml 0.25% bupivacaine
Number of subjects: 40
Study 31623572 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular QLB (QLB‐3)
Number of subjects: 40
Study 30160789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO)
Number of subjects: 82
Study 30160789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Realgar-Indigo naturalis formula (RIF)
Number of subjects: 82
Study 27434598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Conjoint Therapy for PTSD (CBCT for PTSD)
Number of subjects: 40
Study 27434598 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 40
Study 25112087 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreading moxibustion
Number of subjects: 60
Study 25112087 — intervention group
Group type: COMPARATOR
Intervention: Calcium tablets (caltrate, 600 mg per day)
Number of subjects: 60
Study 25112087 — intervention group
Group type: COMPARATOR
Intervention: Calcium tablets
Number of subjects: 60
Study 21838764 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based pedometer programme
Number of subjects: 49
Study 21838764 — intervention group
Group type: COMPARATOR
Intervention: Control group (letter about diabetes risk reduction)
Number of subjects: 49
Study 19657398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg daily
Number of subjects: 921
Study 19657398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study 19657398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 921
Study 17226908 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ciprofloxacin treatment (200 mg intravenous injection for 30 min before ERCP and continued until 48 hours after ERCP)
Number of subjects: 48
Study 17226908 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous ciprofloxacin treatment (200 mg intravenous injection for 30 min before ERCP and discontinued after ERCP)
Number of subjects: 48
Study 15891132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine‐pyrimethamine
Number of subjects: 1105
Study 15891132 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine
Number of subjects: 1105
Study 12086757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=63)
Number of subjects: 190
Study 12086757 — intervention group
Group type: EXPERIMENTAL
Intervention: rFGF-2 (30 microg/kg) on day 1 and placebo on day 30 (single-dose, n=66)
Number of subjects: 190
Study 12086757 — intervention group
Group type: EXPERIMENTAL
Intervention: rFGF-2 (30 microg/kg) on days 1 and 30 (double-dose, n=61)
Number of subjects: 190
Study 9869229 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pelvic irradiation
Number of subjects: 201
Study 9869229 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only treatment
Number of subjects: 201
Study 8594524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb ReNu (multipurpose contact lens care solution)
Number of subjects: 73
Study 8594524 — intervention group
Group type: COMPARATOR
Intervention: Bausch & Lomb Sensitive Eyes (physiological saline)
Number of subjects: 73
Study 2470081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue pleurodesis
Number of subjects: 0
Study 2470081 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline pleurodesis
Number of subjects: 0
Study 937643 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative cholangiography and extraductal palpation
Number of subjects: 1000
Study 937643 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine extraductal palpation and selective cholangiography
Number of subjects: 1000
Study 31337697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage group (n = 20) - Continuous lavage by an automated PD machine from day 3 to 5 or 6
Number of subjects: 40
Study 31337697 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20) - Usual PD schedule maintained
Number of subjects: 40
Study 31337697 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20) - Stratified by CRP tertiles
Number of subjects: 40
Study 31337697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage group (n = 20) - Stratified by CRP tertiles
Number of subjects: 40
Study 28870486 — intervention group
Group type: EXPERIMENTAL
Intervention: VitVOO (vitaminized olive oil)
Number of subjects: 60
Study 28870486 — intervention group
Group type: COMPARATOR
Intervention: PlaVOO (placebo)
Number of subjects: 60
Study 25381051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (dose levels of 1.25-12.5 mg/kg/day and fixed dose of 560 mg/day)
Number of subjects: 245
Study 25381051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (fixed dose level of 560 mg/day)
Number of subjects: 245
Study 25381051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (fixed dose levels of 420 and 840 mg/day)
Number of subjects: 245
Study 25381051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 245
Study 23476053 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided (EG) transvenous LV lead placement
Number of subjects: 187
Study 23476053 — intervention group
Group type: COMPARATOR
Intervention: Routine fluoroscopic approach (Control)
Number of subjects: 187
Study 21676221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5‐10 mg daily for 7 days
Number of subjects: 60
Study 21676221 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 60
Study 19366273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 25 mg ketamine lozenge
Number of subjects: 6
Study 19366273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 25 mg ketamine lozenge
Number of subjects: 6
Study 19366273 — intervention group
Group type: EXPERIMENTAL
Intervention: Norketamine/ketamine area under the plasma concentration-time curve
Number of subjects: 6
Study 16427197 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma morphine concentrations (173+/‐11 ng/ml)
Number of subjects: 28
Study 16427197 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline days with rising methadone concentrations
Number of subjects: 28
Study 15242427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold alpha-stat
Number of subjects: 60
Study 15242427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pH-stat
Number of subjects: 60
Study 15242427 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm alpha-stat
Number of subjects: 60
Study 15242427 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm pH-stat
Number of subjects: 60
Study 15242427 — intervention group
Group type: COMPARATOR
Intervention: Cold groups (alpha-stat and pH-stat combined)
Number of subjects: 60
Study 15242427 — intervention group
Group type: COMPARATOR
Intervention: Warm groups (alpha-stat and pH-stat combined)
Number of subjects: 60
Study 15242427 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia-assisted rapid opioid detoxification with naltrexone induction
Number of subjects: 106
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-assisted rapid opioid detoxification with naltrexone induction
Number of subjects: 106
Study 16118380 — intervention group
Group type: COMPARATOR
Intervention: Clonidine-assisted opioid detoxification with delayed naltrexone induction
Number of subjects: 106
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia-assisted detoxification
Number of subjects: 106
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-assisted detoxification
Number of subjects: 106
Study 16118380 — intervention group
Group type: COMPARATOR
Intervention: Clonidine-assisted detoxification
Number of subjects: 106
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone induction (50 mg)
Number of subjects: 106
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 106
Study 16118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia procedure
Number of subjects: 106
Study 10332529 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based program for identifying drug-related problems
Number of subjects: 246
Study 10332529 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based program
Number of subjects: 246
Study 7990904 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (772 patients)
Number of subjects: 1556
Study 7990904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (784 patients)
Number of subjects: 1556
Study 2253982 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA Cream applied 1 hour prior to venous cannulation
Number of subjects: 75
Study 2253982 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied 1 hour prior to venous cannulation
Number of subjects: 75
Study 7418714 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg methotrexate bolus intravenous injection
Number of subjects: 6